82030 Federal Register / Vol. 75, No. 249 / Wednesday, December 29, 2010 / Notices 

on the Internet at http://www.gsa.gov/ 

ftr. This process, implemented in FTR 

Amendment 2010–07 (75 FR 72965, 

Nov. 29, 2010), ensures more timely 

updates in mileage reimbursement rates 

by GSA for Federal employees on 

official travel. Notices published 

periodically in the Federal Register, 

such as this one, and the changes posted 

on the GSA Web site, now constitute the 

only notification of revisions to 

privately owned vehicle reimbursement 

rates for Federal agencies. 

Dated: December 21, 2010. 

Janet Dobbs, 

Acting Deputy Associate Administrator. 

[FR Doc. 2010–32773 Filed 12–28–10; 8:45 am] 

BILLING CODE 6820–14–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, 

National Center for Health Statistics 

(BSC, NCHS) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), NCHS 

announces the following meeting of the 

aforementioned committee: 

Times and Dates: 11 a.m.–5:30 p.m., 

January 27, 2011. 8:30 a.m.–2 p.m., January 

28, 2011. 

Place: NCHS Headquarters, 3311 Toledo 

Road, Hyattsville, Maryland 20782. 

Status: This meeting is open to the public; 

however, visitors must be processed in 

accordance with established federal policies 

and procedures. Pre-approval is required for 

foreign nationals or non-US citizens. Please 

contact Althelia Harris, 301–458–4261, 

adw1@cdc.gov or Virginia Cain, 

vcain@cdc.gov at least 10 days in advance for 

requirements. All visitors are required to 

present a valid form of picture identification 

issued by a State, Federal or international 

government. The meeting room 

accommodates approximately 100 people. 

Purpose: This committee provides advice 

and makes recommendations to the 

Secretary, HHS; the Director, CDC; and the 

Director, NCHS, regarding the scientific and 

technical program goals and objectives, 

strategies, and priorities of NCHS. 

Matters to be Discussed: The agenda will 

include welcome remarks by the Director, 

NCHS; an update on the Health Indicators 

Warehouse; an update on program reviews; 

and an open session for comments from the 

public. 

Requests to make oral presentations should 

be submitted in writing to the contact person 

listed below. All requests must contain the 

name, address, telephone number, and 

organizational affiliation of the presenter. 

Written comments should not exceed five 

single-spaced typedpages in length and must 

be received by January 21, 2011. 

The agenda is subject to change as 

priorities dictate. 

Contact Person for More Information: 

Virginia S. Cain, PhD, Director of Extramural 

Research, NCHS/CDC, 3311 Toledo Road, 

Room 7211, Hyattsville, Maryland 20782, 

telephone (301) 458–4500, fax (301) 458– 

4020. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and othercommittee 

management activities, for both the 

Centers for Disease Control and 

Prevention, and the Agency for Toxic 

Substances and Disease Registry. 

Dated: December 21, 2010. 

Elaine L. Baker, 

Management Analysis and Services Office, 

Centers for Disease Control and Prevention. 

[FR Doc. 2010–32747 Filed 12–28–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0640] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Data to Support 

Food and Nutrition Product 

Communications, as Used by the Food 

and Drug Administration 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing an 

opportunity for public comment on the 

proposed collection of certain 

information by the Agency. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), Federal Agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information and to allow 60 days for 

public comment in response to the 

notice. This notice solicits comments on 

a generic clearance to collect 

information to support communications 

about nutrition and food products 

regulated by FDA. This data collection 

will gauge, informally, public opinion 

on a variety of subjects related to 

consumer, patient, or health care 

professional perceptions and use of 

nutrition and food products and related 

materials, including but not limited to, 

food advertising, food and nutrition 

labeling, emerging risk communications, 

online sales of food products, and 

consumer and professional education. 

DATES: Submit either electronic or 

written comments on the collection of 

information by February 28, 2011. 

ADDRESSES: Submit electronic 

comments on the collection of 

information to http:// 

www.regulations.gov. Submit written 

comments on the collection of 

information to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. All 

comments should be identified with the 

docket number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: 

Denver Presley, Jr., Office of Information 

Management, Food and Drug 

Administration, 1350 Piccard Dr., PI50– 

400B, Rockville, MD 20850, 301–796– 

3793. 

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3520), Federal 

Agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 

information they conduct or sponsor. 

‘‘Collection of information’’ is defined in 

44 U.S.C. 3502(3) and 5 CFR 1320.3(c) 

and includes Agency requests or 

requirements that members of the public 

submit reports, keep records, or provide 

information to a third party. Section 

3506(c)(2)(A) of the PRA (44 U.S.C. 

3506(c)(2)(A)) requires Federal Agencies 

to provide a 60-day notice in the 

Federal Register concerning each 

proposed collection of information 

before submitting the collection to OMB 

for approval. To comply with this 

requirement, FDA is publishing notice 

of the proposed collection of 

information set forth in this document. 

With respect to the following 

collection of information, FDA invites 

comments on these topics: (1) Whether 

the proposed collection of information 

is necessary for the proper performance 

of FDA’s functions, including whether 

the information will have practical 

utility; (2) the accuracy of FDA’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques, 

when appropriate, and other forms of 

information technology. 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 75, No. 249 / Wednesday, December 29, 2010 / Notices 82031 

Data to Support Food and Nutrition 

Product Communications, as Used by 

the Food and Drug Administration—21 

U.S.C. 393(d)(2)(D) (OMB Control 

Number 0910–NEW) 

FDA plans to use the data collected 

under this generic clearance to inform 

its nutrition and foods communications 

campaigns. FDA expects the data to 

guide the formulation of its food and 

nutrition communication objectives. 

FDA also plans to use the data to help 

tailor print, broadcast, and use 

electronic media communications in 

order for them to have powerful and 

desired impacts on target audiences. 

The data will not be used for the 

purposes of making policy or regulatory 

decisions. 

The information collected will serve 

two major purposes. First, as formative 

research, it will provide the critical 

knowledge needed about target 

audiences. FDA must explore 

audiences’ beliefs, perceptions, and 

decisionmaking processes about 

nutrition and food consumption in 

order to formulate the basic objectives of 

its risk communication campaigns. Such 

knowledge will provide the needed 

target audience understanding to design 

effective communication strategies, 

messages, and product labels. These 

communications will aim to improve 

public understanding of the risks and 

benefits of consuming certain foods or 

nutritional products by providing users 

with a better context in which to place 

risk information more completely. 

Second, as initial testing, it will give 

FDA some information about the 

potential effectiveness of messages and 

materials in reaching and successfully 

communicating with their intended 

audiences. Testing messages with a 

sample of the target audience will allow 

FDA to refine messages while still in the 

developmental stage. Respondents may 

be asked to give their reaction to the 

messages in individual or group 

settings. 

FDA’s Center of Food Safety and 

Applied Nutrition, Office of the 

Commissioner, and other Centers or 

Offices will use this mechanism to test 

messages about regulated food and 

nutrition products on a variety of 

subjects related to consumer, patient, or 

health care professional perceptions and 

use of foods and related materials, 

including but not limited to, food 

advertising, food and nutrition labeling, 

emerging risk communications, online 

sales of food products, and consumer 

and professional education. The data 

will not be used for the purposes of 

making policy or regulatory decisions. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

Number of 

respondents 

Annual 

frequency 

per response 

Total 

annual 

responses 

Hours per 

response 

Total 

hours 

Individual indepth interviews ............................................................ 360 1 360 0.75 270 

General public focus group interviews ............................................ 144 1 144 1.5 216 

Intercept interviews: central location ............................................... 600 1 600 0.25 150 

Intercept interviews: telephone ........................................................ 10,000 2 1 10,000 0.08 800 

Self-administered surveys ................................................................ 2,400 1 2,400 0.25 600 

Gatekeeper reviews ......................................................................... 400 1 400 0.50 200 

Omnibus surveys ............................................................................. 2,400 1 2,400 0.17 408 

Total (general public) ................................................................ 16,304 ........................ 16,304 ........................ 2,644 

Total physician focus group interviews .................................... 144 1 144 1.5 216 

Total (overall) ............................................................................ ........................ ........................ ........................ ........................ 2,860 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

2Brief interviews with callers to test messages, concepts and strategies following their call-in request to an FDA Center 1–800 number. 

Annually, FDA projects about 30 

communication studies using the 

variety of test methods listed in table 1. 

FDA is requesting this burden so as not 

to restrict the Agency’s ability to gather 

information on public sentiment for its 

proposals in its regulatory and 

communications programs. 

Dated: December 22, 2010. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2010–32739 Filed 12–28–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Pulmonary-Allergy Drugs Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: PulmonaryAllergy Drugs Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the Agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on March 8, 2011, from 8 a.m. to 

5 p.m. 

Location: FDA White Oak Campus, 

10903 New Hampshire Ave., Building 

31 Conference Center, the Great Room, 

(rm. 1503), Silver Spring, MD 20993– 

0002. Information regarding special 

accommodations due to a disability, 

visitor parking and transportation may 

be accessed at: http://www.fda.gov/ 

AdvisoryCommittees/default.htm; under 

the heading ‘‘Resources for You,’’ click 

on ‘‘White Oak Conference Center 

Parking and Transportation Information 

for FDA Advisory Committee Meetings.’’ 

Please note that visitors to the White 

Oak Campus must enter through Bldg 1. 

Contact Person: Kristine T. Khuc, 

Center for Drug Evaluation and 

Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave, Bldg. 31, rm. 2417, Silver Spring, 


srobinson on DSKHWCL6B1PROD with NOTICES